S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

Similar documents
S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

Carcinoma of the Urinary Bladder Histopathology

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Carcinoma of the Renal Pelvis and Ureter Histopathology

Gastric Cancer Histopathology Reporting Proforma

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

*OPERATIVE PROCEDURE. Serum tumour markers within normal limits S1.04 PRINCIPAL CLINICIAN

Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

Recommendations for the Reporting of Prostate Carcinoma

Prostate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018

Diagnosis, pathology and prognosis including variant pathology

Vulva Cancer Histopathology Reporting Proforma

Definition of Synoptic Reporting

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD

3/28/2017. Disclosure of Relevant Financial Relationships. GU Evening Subspecialty Case Conference. Differential Diagnosis:

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Update on Reporting Prostate Cancer Pathology

GUIDELINES ON PROSTATE CANCER

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma

Prostate Case Scenario 1

FNA Thyroid Cytology Structured Reporting Proforma

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

Kidney Case 1 SURGICAL PATHOLOGY REPORT

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

They Do Look Alike : Mimics of Prostate Cancer in Biopsy Samples

Urinary Bladder, Ureter, and Renal Pelvis

Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.

A215- Urinary bladder cancer tissues

Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance

VULVAR CARCINOMA. Page 1 of 5

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

LOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.

Collaborative Staging

Prostate cancer grading: a decade after the 2005 modified system

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT

ACCME/Disclosures. Cribriform Lesions of the Prostate. Case

CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release

Retinoblastoma. Protocol applies to retinoblastoma only.

Uveal Melanoma. Protocol applies to malignant melanoma of the uvea.

Descriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma

Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted

Case Scenario 1: Breast

The pathology of bladder cancer

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition

Protocol for the Examination of Specimens from Patients with Carcinoma of the Prostate Gland

Diagnosis of prostate cancer

SEER Summary Stage Still Here!

3. Guidelines for Reporting Bladder Cancer, Prostate Cancer and Renal Tumours

ADENOCARCINOMA OF THE PROSTATE

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Prostate Overview Quiz

Grading Prostate Cancer: Recent Changes and Refinements

FINALIZED SEER SINQ QUESTIONS

PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

Supplemental Figure 1

PROSTATE CANCER (RADICAL PROSTATECTOMY) STRUCTURED REPORTING PROTOCOL (3rd Edition 2018)

Pathology of the Prostate. PathoBasic Tatjana Vlajnic

Update on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.

TOPICS FOR DISCUSSION

Neoplasms of the Prostate and Bladder

Boot Camp Case Scenarios

Gleason grading and prognostic factors in carcinoma of the prostate

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

OMPRN Pathology Matters Meeting 2017

Select problems in cystic pancreatic lesions

Seventh Edition Staging 2017 Breast

Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do?

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

PLACE LABEL HERE. ACRIN 6659 Registration/Eligibility Institution

B REAST STAGING FORM. PATHOLOGIC Extent of disease through completion of definitive surgery. CLINICAL Extent of disease before any treatment

GUIDELINEs ON PROSTATE CANCER

Protocol applies to melanoma of cutaneous surfaces only.

Some prostatic diseases

RENAL CELL CARCINOMA 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a Pseud

Chapter 2. Understanding My Diagnosis

PROSTATE CANCER (TRANSURETHRAL RESECTION AND ENUCLEATION) STRUCTURED REPORTING PROTOCOL (1 st Edition 2018)

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Genitourinary Neoplasms Updated for 2012 Requirements and CSv02.04

Transcription:

Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate Ethnicity Unknown Aboriginal/Torres Strait Islander ethnicity: Patient identifiers e.g. MRN, IHI or NHI (please indicate which) Date of request S1.03 Accession number Requesting doctor - name and contact details Clinical details Surgical procedure S1.04 Principal clinician G1.01 Coents Nature of specimen Clinical history (including Gleason grade and score of previous specimens) Macroscopic findings Previous therapy S2.01 *Specimen weight (ie Prostate without seminal vesicles) g G2.01 *Specimen dimensions (prostate) length x width x thickness *Pre-biopsy serum PSA ng/ml Or Not available Relevant clinical info. for clinicopathological staging S2.02 *Seminal vesicles (partially or completely resected) Vers. 2.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 2nd Edition Page 1 of 5

S2.03 *Lymph nodes G2.02 *Laterality Left Right Bilateral Site 1 Number of LNs/site Site 2 Number of LNs/site G2.03 *Block identification key G3.01 TUMOUR LOCATION Largest nodule located by quadrant Right anterior Right posterior Left anterior Left posterior Largest nodule located by plane Apex Mid Base of prostate nodules >10 in diameter Location by plane and quadrant: Right anterior Right posterior Left anterior Left posterior Apex Mid Base of prostate G3.02 *Intraglandular extent % G3.03 *Maximum size of dominant nodule S3.02 *HISTOLOGICAL GRADE (REFER P5) G2.04 Additional macroscopic coents *Primary Gleason grade 1 2 3 4 5 *Secondary Gleason grade 1 2 3 4 5 *Tertiary Gleason grade 3 4 5 Microscopic findings S3.01 *Histological tumour type Adenocarcinoma (Acinar, usual type) Adenocarcinoma (Acinar variant eg. Foamy, Pseudohyperplastic) (specify type) *Gleason Score Prostatic ductal adenocarcinoma Adenosquamous carcinoma Small cell carcinoma Sarcomatoid carcinoma Undifferentiated carcinoma, not otherwise specified Vers. 2.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 2nd Edition Page 2 of 5

S3.03 *Extraprostatic extension Not identified Indeterminate G3.04 *Location(s) of EPE (Select all that apply) Apical Bladder neck Anterior Lateral Postero-lateral Posterior G3.08 *Bladder neck Not involved Involved S3.07 *LYMPH NODES STATUS *Number of lymph nodes examined *Number of positive lymph nodes S3.04 *Extent Non-focal Focal S3.05 *Margin status Involved Not involved Indeterminate G3.09 *Laterality Left Right Bilateral *Location(s) (Select all that apply) Apical Lateral Bladder neck Postero-lateral Anterior Posterior Site(s) of involved nodes G3.05 *Extent (total) G3.10 *Maximum dimension of largest deposit (If more than 1 positive margin, record the cuulative length) G3.06 *Gleason score at margin G3.11 *Lymphovascular invasion Not identified Indeterminate (If more than 1 positive margin, record the higest score) G3.12 Additional microscopic coent G3.07 *Type of margin positivity EPE Intraprostatic (capsular incision) S3.06 *Seminal vesicles Not involved Involved Left side Right side Both Vers. 2.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 2nd Edition Page 3 of 5

Synthesis and overview S5.01 *PATHOLOGICAL STAGING (AJCC 7TH EDITION)** *Primary tumour (T) *Regional lymph nodes (N) *Distant metastasis (M) OR S5.02 Year and edition of staging system G5.01 Diagnostic suary Include specimen type, tumour type, Gleason score, tumour stage, involvement of surgical margins AJCC TNM definitions ## Pathologic primary tumor (T) ptx Primary tumor cannot be assessed pt0 No evidence of primary tumor * pt2 Organ Confined pt2a Unilateral, one-half of one side or less pt2b Unilateral, involving more than one-half side but not both sides pt2c Bilateral disease pt3 Extraprostatic extension pt3a Extracapsular extension or microscopic invasion of bladder neck** pt3b Seminal vesicle invasion pt4 Invasion of rectum, levator muscles and/or pelvic wall. Notes: 1. Invasion into the prostate apex or into (but not beyond) the prostate capsule is not classified as T3, but as T2. * Note: There is no pathologic T1 classification for radical prostatectomy ** Note: Positive surgical margin should be indicated by an R1 descriptor (residual microscopic disease) Pathologic regional lymph nodes (N) pnx Regional lymph nodes not sampled. pn0 No positive regional nodes. pn1 Metastasis in regional node(s). S5.03 Overarching coent Clinical and pathologic distant metastasis (M) M0 No distant metastasis. M1 Distant metastasis M1a Non-regional lymph node(s)* M1b Bone(s) M1c site(s) with or without bone disease *Notes: When more than one site of metastasis is present, the most advanced category is used. pm1c is most advanced. ## Used with the permission of the American Joint Coittee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com. Worksheet prepared by: On: Vers. 2.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 2nd Edition Page 4 of 5

S3.02 HISTOLOGICAL GRADE Gleason grade 1 Closely packed small regular glands forming a circumscribed rounded nodule Very rarely use in radical prostatectomy specimen reports. Do not use for needle biopsy specimens 2 Glands more loosely arranged; not quite as uniform; fairly circumscribed but may have minimal infiltration at margins May be used in radical prostatectomy and TURP specimen reports. Do not use for needle biopsies 3 Discrete glandular units/acini with marked variation in size and shape; infiltrates in and amongst benign prostatic tissue Very rarely cribriform (see below) 4 Fused micro acinar glands; ill-defined glands with poorly formed lumina; large cribriform irregular glands; hypernephroid 5 Minimal if any glandular differentiation solid sheets, cords or single cells. Comedocarcinoma Gleason score Number of different grades present Proportion of grades present 1 One of 2, 3, 4 or 5 only 2 Primary and secondary 3 Primary, secondary and tertiary Notes: Grades mixed Secondary grade is lower and of limited amount (<5%) Secondary grade is higher and of limited amount (<5%) Grades 2, 3, 4 or 5 Coents Double grade to get score (eg 4+4=8) nondominant (smaller) nodule if of higher grade (if present) Report both grades, dominant pattern* first (2+3, 3+4, 4+3..) nondominant (smaller) nodule if of higher grade (if present) Ignore lower grade 4+3 becomes 4+4 Include higher grade 3+3 becomes 3+4 Report dominant grade (largest area) first, then secondary grade (second largest area), then tertiary grade (only if 4 or 5) eg 3+4=7 with tertiary grade 5 eg 2+3=5 with tertiary grade 4 Dominant (primary) grade is that which occupies the greatest area. For radical prostatectomy specimens secondary grade is defined as that which occupies the second greatest area. For radical prostatectomy specimens tertiary grade is defined as that which occupies the third greatest area (provided that it is higher than the primary and secondary grades). Gleason scoring of unusual patterns Pattern Morphology Coent Vacuoles Mucin extravasation Mucinous fibroplasia Glomeruloid structures Foamy gland change Small cell neuroendocrine Gleason scoring of cribriform patterns Grade 3 Grade 4 Grade 5 PIN Intraductal carcinoma Cytoplasmic change seen in all grades Collagenous micronodules Small, well circumscribed, round with smooth regular edges Rare. Should be used only rarely in scoring Irregular cribriform and fused gland masses Should include nearly all cribriform patterns Any cribriform area with necrosis Comedonecrosis Do not include in score Branched architecture of high grade intraductal proliferation filling lumen Include as Grade 4 (or 5 if comedonecrosis) PIN = prostatic intraepithelial neoplasia Grade as if vacuoles were absent, on the underlying architecture Grade as 4 Do not assign a grade Vers. 2.0 Proforma: Prostate Cancer (Radical Prostatectomy) Structured Reporting Protocol 2nd Edition Page 5 of 5